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50 Trans-Splicing Repair of the PLEC1 Gene
Verena Wally1, Alfred Klausegger1, Ulrich Koller1, Hanns Lochmu¨ller2, Sabine Krause2, Gerhard Wiche3,
Lloyd G. Mitchell4, Helmut Hintner1 and Johann W. Bauer1
The efficient treatment of hereditary disorders, especially of those caused by dominant-negative mutations still
remains an obstacle to be overcome. Allele specificity is a critical aspect that must be addressed by silencing
therapies such as small interfering RNA, which has the potential risk of also reducing expression of the normal
allele. To overcome this hurdle, we used spliceosome-mediated RNA trans-splicing (SMaRT) to replace mRNA
exon segments in an in vitro disease model. In this model, a heterozygous insertion of a leucine codon into
exon 9 of the plectin gene (PLEC1) leads to aggregation of plectin peptide chains and subsequent protein
degradation recapitulating, together with a nonsense mutation on the other allele, the blistering skin disease
epidermolysis bullosa simplex with muscular dystrophy (EBS-MD). Transient transfection of EBS-MD fibroblasts
with a 50 pre-trans-splicing molecule encoding wild-type exons 2–9 led to specific replacement of the mutated 50
portion of the endogenous PLEC1 transcript through trans-splicing. This treatment reduced the levels of mutant
mRNA and restored a wild-type pattern of plectin expression as revealed by immunofluorescence microscopy.
When EBS-MD fibroblasts were transfected with retroviral constructs, the level of full-length plectin protein in
the corrected fibroblasts increased by 58.7%. Thus, SMaRT may be a promising new tool for treatment of
autosomal-dominant genetic diseases.
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INTRODUCTION
Reprogramming of pre-mRNAs by means of spliceosome-
mediated RNA trans-splicing (SMaRT) is based on exploiting
the naturally occurring splicing events required for pre-
mRNA maturation (Puttaraju et al., 1999). SMaRT utilizes the
endogenous splicing machinery to recombine two indepen-
dent RNA molecules by trans-splicing, replacing the disease-
causing portion of a pre-mRNA with an engineered sequence
in an exon-specific manner. These reactions are affected by
engineered pre-trans-splicing molecules (PTMs) that contain
a binding region to base pair specifically with the targeted
intron of a pre-mRNA, thus facilitating trans-splicing between
the PTM and the target pre-mRNA. In this case, the PTM
brings in the wild-type coding region to be trans-spliced to
the target using a functional 50 splice site.
Trans-splicing can replace either the 30, 50, or internal
exon(s) of the pre-mRNA target, referred to as 30-, 50-, or
internal exon replacement. Of these methods, the 30 trans-
splicing strategy is the most commonly used. 50 trans-splicing
has been used in a double transfection experiment to
reprogram mutations in plasmid-encoded cystic fibrosis
transmembrane receptor (CFTR) and b-globin genes (Mans-
field et al., 2003; Kierlin-Duncan and Sullenger, 2007), but
has not been reported for an endogenous gene target at this
time. Successful and safe 30 trans-splicing therapy has been
demonstrated in animal models of autosomal-recessive
genetic diseases such as cystic fibrosis, X-linked immuno-
deficiency, and hemophilia (Liu et al., 2002; Chao et al.,
2003; Tahara et al., 2004).
Several advantages of trans-splicing have been considered
in the past. First, the natural expression pattern of the target
gene is retained. Second, the segmental introduction of
therapeutic molecules allows much smaller correcting
molecules to be used (for a review see Chao and Walsh,
2006). Third, trans-splicing converts the mutant allele to wild
type, thereby not only knocking down expression of a
mutated allele, but also increasing the level of normal protein
beyond that provided by simply ablating the mutant form.
This makes it especially appealing for dominant-negative
mutations. However, no experimental evidence has been
shown yet for this third point.
After considering the disadvantages of specificity, effi-
ciency, safety, and sequence limitations associated with other
possible nucleotide therapeutic approaches (such as RNAi,
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ribozymes, and antisense), we chose to develop SMaRT as a
potential treatment of mutation in large genes that act in a
dominant-negative manner.
We used cells from patients suffering from epidermolysis
bullosa as a model system to study the 50 SMaRT approach.
Mutations in the plectin gene (PLEC1) underlie epidermolysis
bullosa simplex with late onset muscular dystrophy (EBS-
MD). At 14.2 kb, PLEC1 produces one of the largest known
mRNAs and exceeds the packaging capacity of most viral
vectors. PLEC1 encodes a large cytolinker protein that
anchors and connects the keratinocyte cytoskeleton to the
hemidesmosomes. The skin and muscles of patients with EBS-
MD are (severely) affected by the fragility of the mutated
cellular anchoring structures, leading to the development of
blisters and skin erosions. In this study, we used cells derived
from a compound heterozygous patient with a 3 bp insertion
in exon 9 (1287ins3) and a nonsense mutation in exon 31
(Q1518X) of the PLEC1 gene. The insertion of a CTG in
position 1287 leads to the incorporation of an additional
leucine at position 429 on protein level, which increases the
hydrophobicity in this region and may lead to changes in
conformation. A previous study showed that this additional
leucine residue promotes self-aggregation, resulting in the
degradation of full-length plectin protein in the presence of
unaltered PLEC1 mRNA levels. This molecular constellation
(i.e., preserved mRNA expression levels, but a protein
product produced by one allele affecting the overall function
of the molecule) can also be seen in dominantly inherited
forms of EB, EB simplex, and dystrophicans. This mechanism
allows us to use these patient-derived cells as a model for a
dominant-negative gene product (Bauer et al., 2001). On the
basis of these considerations, we transduced EBS-MD cells with
a PTM designed to repair any mutation in the 50 coding region
of the PLEC1 gene and demonstrated the applicability of trans-
splicing for the treatment of hereditary diseases of the skin.
RESULTS
Endogenous trans-splicing in the PLEC1 gene
Primary fibroblasts derived from an EBS-MD patient hetero-
zygous for the PLEC1 mutations 1287ins3/Q1518X were
immortalized to prevent senescence of the cells during the
experimental procedures. The immortalized cells were
morphologically indistinguishable from both normal fibro-
blasts and untreated cells from the patient. Furthermore, the
presence of the insertion mutation in exon 9 of the
immortalized cells was confirmed by sequencing (data not
shown). A PTM-E50 was designed to contain features specific
to 50 trans-splicing (Figure 1; Mansfield et al., 2003). These
are as follows: (i) a 50-bp binding domain complementary to
both the last 40 nucleotides of intron 9 of the targeted plectin
pre-mRNA and the first 10 nucleotides of exon 10; (ii) a 183-
bp spacer region; (iii) the wild-type plectin exons 2–9, which
encompass 1026nt (exon 1 is an alternative exon); (iv) the
functional plectin intron-9 50 splice site and an intronic
splicing activator and repressor sequence; (v) a cytomegalo-
virus promoter and an SV40 polyadenylation signal. The
plasmid expressing this PTM was transiently transfected into
immortalized patient fibroblasts to test for trans-splicing
repair of endogenous plectin mRNA. Levels of normal and
mutant plectin mRNA were measured by semiquantitative
real-time PCR (SQRT-PCR), amplifying complementary DNA
(cDNA) from wild-type fibroblasts, transfected and non-
transfected EBS-MD fibroblasts. A wild-type specific forward
PCR primer was designed to discriminate between wild-type
and mutated mRNA molecules by inclusion of the four wild-
type gct repeats in exon 9. The reverse primer was
complementary to PLEC1 exon 10 (Figure 2a). Analysis of
the PCR products from wild-type fibroblasts showed the
expected 189-bp band, representing the wild-type allele.
After transient transfection with PTM-E50, wild-type plectin
cDNA levels were increased by an average of 83.42% as
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Figure 1. Schematic depiction of the endogenous target in EBS-MD cells and the PTM-E50. The binding region (BD) is complementary to the last 40
bases of intron 9 and the first 10 bases of exon 10 of the endogenous target plectin pre-mRNA. Trans-splicing results in a mature corrected mRNA
combining wild-type exons 2–9 brought in by the PTM, and exons 10–32 of the endogenous PLEC1 target pre-mRNA. ISAR, intronic splicing activator and
repressor; PPT, polypyrimidine tract; 50 and 30 ss, splice sites.
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measured by SQRT-PCR in four independent experiments
(Figure 2b and c).
Specificity of trans-splicing determined by cross-gene PCR
Members of the plakin gene family, including plectin, show
high sequence homology, thus constituting a model group of
genes to evaluate illegitimate, nonspecific PTM trans-
splicing. PCR primers were designed to amplify exons
flanking sequences with the highest homology to the PTM-
binding domain for six plakin family genes desmoplakin,
envoplakin, epiplakin, dystonin, periplakin, and microtubule-
actin crosslinking factor 1. Cross-gene PCR between these
plakin family genes and exon 9 of PLEC1 was performed.
These PCRs revealed only the expected plectin-specific
control band at 216 bp (Figure 3). Some nonspecific PCR
bands were produced, which were also detected in the cross-
gene PCR analysis of non-transfected patient fibroblasts,
using the same primers. Nonspecific bands were cloned into
TOPO-TA and sequenced, confirming them not to be
nonspecific trans-splicing products but nonspecific PCR
products. These results demonstrate a high level of 50 trans-
splicing specificity in the plakin gene family.
Plectin repair restores the expression of plectin-containing
structures
Wild-type fibroblasts display intense plectin staining through-
out the cytoplasm (Figure 4a). Previous studies of EBS-MD
cells from a distinct family showed increased self-aggregation
of mutant plectin polypeptides by an in vitro overlay assay
(Bauer et al., 2001). These aggregates were also visualized in
the cytoplasm of untreated patient fibroblasts (Figure 4c) by
immunofluorescence-optical analysis using the plectin-
specific mAb 5B3 (Foisner et al., 1994). In cells transiently
transfected with PTM-E50, we observed the generation of the
characteristic plectin-containing structures as well as a
reduction of aggregates in about 30% of the cells (Figure 4b).
PTM-R50 delivered by a retroviral vector generates expression
of full-length plectin protein
To test the feasibility of retroviral delivery, we cloned the
PTM into the retroviral vector pLXSN (PTM-R50). PTM-R50
was transfected into the host cell line PT67 and virus was
produced following the manufacturer’s protocol. Positive
supernatants were used for viral titer determination (Figure 5).
Five-hundred microliters of PTM-R50-positive viral super-
natant (VS1) with a titer of 2 106 colony forming units (CFU)
per ml were used for the infection of 2106 primary EBS-MD
fibroblasts. The expression of full-length plectin protein was
evaluated by western blot analysis. Total protein was
extracted from VS1-infected EBS-MD fibroblasts after 3 days
of culture without G418 selection to avoid geneticin-
associated readthrough of the stop codon Q1518X on the
second allele. A B500 kDa band was detected in samples
from infected cells and comigrated with the plectin protein
band of wild-type fibroblasts. This band was only 18.22% in
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Figure 2. Real-time PCR of transfected patient cells. (a) A specific primer
amplifies the wild-type strand only. I: PCR using the wild-type-specific
forward primer (see Materials and Methods) in combination with a reverse
primer specific to exon 10. Lane a: PCR of patient cDNA encompassing
position 1026. Lane b: cDNA from an unaffected person. II: As a reference,
the same amount of cDNA was used for PCR with primers specific to the
housekeeping gene GAPDH. (b) SQRT-PCR showing an increase of the wild-
type mRNA in PTM-transfected versus -non-transfected EBS-MD fibroblasts.
Five SQRT-PCR runs of three independent transfection experiments are
shown. (c) A mean increase of the wild-type allele of 83.42% after 48 hours
was detected.
216 bp
Figure 3. Cross-gene PCR analysis for plectin and related plakin genes
showed specificity of the 50 trans-splicing process. We detected no specific
bands except for the plectin control (216 bp) in PTM-R50-infected patient
cells. Some nonspecific bands (lanes 1, 3, 4, and 7) also occurred in the non-
transfected EBS-MD fibroblasts (data not shown). Thus they can be regarded
as nonspecific PCR products. Lane 1: reverse primer for desmoplakin; lanes
2–8, microtubule-actin crosslinking factor 1; lanes 9–11, dystonin; lane 12,
epiplakin; lane 13, envoplakin; lanes 14 and 15, periplakin.
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non-transfected EBS-MD cells compared to wild-type fibro-
blasts and increased to 28.93% in infected cells, as detected
by densitometric measurements. This means an increase of
58.78% of full-length plectin protein in total protein extracts
of infected fibroblasts compared to non-infected fibroblasts
(Figure 6a and b). This increase roughly correlates also with
the results of the SQRT-PCR.
DISCUSSION
In this study, we demonstrate 50 SMaRT to be a functional
tool for the correction of any mutation in an upstream part of
an affected gene/allele.
Using SMaRT trans-splicing-based RNA therapy, a defined
endogenously expressed target pre-mRNA is cleaved and a
new sequence from a trans-splicing molecule is inserted
either upstream, downstream, or within the selected target to
generate a new gene product. Expression of the trans-spliced
gene is regulated by the cellular control elements and the
presence of the target gene. Trans-splicing efficiencies as high
as 50% have been achieved in studies targeting endogenous
human papilloma virus pre-mRNAs in cultured cells from
cervical cancers (unpublished data). Functional restoration of
up to 22% of normal chloride channel activity has been
achieved in a cystic fibrosis xenograft model. This is a level
that could provide therapeutic benefit in the treatment of a
significant number of diseases (Liu et al., 2002). In human
a b c
Figure 4. Restoration of plectin protein expression in PTM-E50-transfected EBS-MD fibroblasts detected by immunofluorescence. Immunofluorescence
pictures and corresponding light microscopy pictures are shown. (a) Wild-type fibroblasts. (b) Representative EBS-MD fibroblasts transiently transfected
with PTM-E50. (c) Non-transfected (mutant) EBS-MD fibroblasts. Bar¼10 mm.
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Figure 5. RT-PCR products of viral supernatant (VS1) of RetroPack PT67
cells transfected with PTM-R50. A PCR product of 1363 bp represents the
correct insert length (lane 4). Lanes 1 and 3 are positive controls for
GAPDH and PTM-R50, respectively. Lane 2 shows the results of a PCR
designed to amplify GAPDH from genomic DNA as a test for genomic DNA
contamination of the viral supernatant.
150
120
90
60
30
0
1 2 3
Figure 6. Restoration of full-length plectin protein in western blotting.
(a) Bars show relative amounts of plectin analyzed by densitometric
scanning. (b) Lane 1: protein from wild-type human fibroblasts showing the
expression of full-length plectin protein. Non-infected EBS-MD fibroblasts
(lane 2). Production of full-length plectin protein (lane 3) in EBS-MD
fibroblasts infected with viral supernatant containing PTM-R50 for 2 days
without selection. One representative blot of three experiments is shown.
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skin cells, we have been able to detect up to 24%
trans-splicing efficiency in a 30 SMaRT approach (Dallinger
et al., 2003).
In the transient transfection assays reported here, 30% of
the EBS-MD cells were plectin-positive by immunofluore-
scence microscopy 7 days after the transfection. Cells that
were positive showed plectin-specific cytoskeletal staining
features (Figure 4). Differences in the staining pattern
compared with wild-type fibroblasts are due to a reduced
amount of plectin protein expressed and a different cellular
distribution due to isoform variations. We used plectin exons
2–9, skipping the alternative exon 1, which is cell type-
specific. Inclusion of exon 1 leads to the expression of an
additional actin and ITGB4-binding site, explaining varia-
tions in the staining pattern (Rezniczek et al., 2003).
These data were corroborated by the western blot analysis
of treated patient fibroblasts. Taking into account a correction
of 10% of unselected retroviral-PTM-infected cells, the
58.78% increase in plectin expression detected in the PTM-
treated cells as suggested by densitometric measurements
implies that plectin levels should increase by more than
500% in retroviral-PTM-transduced cells after selection.
However, G418 selection causes geneticin-associated stop
codon readthrough (Lai et al., 2004), rendering the contribu-
tion of trans-splicing to the overall corrective effect unclear if
selection is employed.
Regardless of these technical considerations, for this
technology to be useful in clinical applications, more
efficient trans-splicing is needed. Although no nonspecific
trans-splicing products were detected in our cross-gene
evaluation of the plakin family of genes, optimization of
PTM specificity might be necessary to achieve higher specific
trans-splicing rates. This can be achieved by the use of high-
capacity screening to identify the optimal binding sequence
for the plectin gene followed by rational design, use of a
tissue-specific promoter, and improvement in transgene
delivery (Puttaraju et al., 2004).
To date, most studies using SMaRT as a therapeutic
approach to treat genetic diseases have focused on 30 exon
replacement. Recently, it was demonstrated that PTMs can
also trans-splice the 50 region of a transcript, replacing the
1.9-kb sequence coding for exons 1–10 of the CFTR gene or
exon 1 of the b-globin gene (Mansfield et al., 2003; Kierlin-
Duncan and Sullenger, 2007). In the first study, a PTM
plasmid was constructed to express a binding domain
complementary to CFTR intron 10 along with a 50 splice site
and the coding sequences of CFTR exons 1–10. This was co-
transfected in cultured human cells together with a target
plasmid that expressed CFTR DF508 exon 10, a mini-intron
10 and exons 11–24. Full-length trans-spliced CFTR mRNAs
(B6% of the cis-spliced target) and functional chloride ion
channels were generated. Our results extend these studies by
demonstrating 50 exon replacement of an endogenous gene.
In summary, we have initiated the first gene therapeutic
approach for plectin, one of the largest human genes with a
14.2 kb mRNA that far exceeds the capacity of current
clinically approved viral vectors. With a single RNA trans-
splicing construct, we demonstrated the capability to correct
all possible mutations over a 1026-nt coding region of the
PLEC1 gene. Our results lead us to conclude that SMaRT may
be a more cost-effective alternative for allele-specific treat-
ment of genetic diseases, requiring the development, testing,
and approval of far fewer products to treat a large number of
different mutations. Furthermore, as trans-splicing does not
involve the endogenous gene suppression pathways, it should
have a different safety profile than the currently favored
allele-specific gene therapy technology RNA interference,
and hopefully fewer off-target effects.
MATERIALS AND METHODS
Immortalization of plectin-deficient (1287ins3/Q1518X)
fibroblasts
Cells were infected with a retroviral vector carrying the E6 and E7
oncogenes (responsible for the promotion of cell proliferation and
immortalization). Transformed cells were then selected for G418
resistance, pooled and maintained in G418-containing medium
(Miller and Rosman, 1989).
Construction of PTMs
The mutation of interest is located in exon 9 at position 1287
(1287ins3) of the plectin gene (PLEC1). Therefore, the 50 region of
PLEC1, consisting of exons 2 (containing the initiation codon) to 9 of
an unaffected person, was amplified by a one-step reverse
transcriptase PCR (SuperScript One-Step RT-PCR with Platinum
Taq; Invitrogen, Lofer, Austria). Exon 1 is a non-coding exon.
A forward primer binding at the 50 end of exon 2, which introduces a
restriction site for cloning (gataagcttgaggccatgtcggg) was used. To
evaluate the functionality of the 30 splice site of exon 9, a reverse
primer with a 15-bp overhang was designed to introduce the first
bases of intron 9 of PLEC1 (shown in italicized letters) and a XhoI
restriction site into the construct (gatctcgagccacggcaggcccact-
caatctcctcgaagct).
Adjacent to the coding region of PLEC1, an intron was
engineered comprising a binding domain (BD) complementary to
intron 9 and the first 10 bases of exon 10 of PLEC1, thus bringing
donor and acceptor splice sites into proximity, which may enhance
trans-splicing. The first 10 bases of exon 10 were included into the
PTM to theoretically block cis-splicing. In addition, an intronic
splicing activator and repressor was introduced downstream of
the PTM donor site, as it may enhance trans-splicing activity.
PTM-E50 was cloned into pcDNA3.1D/V5-His-TOPO (Invitrogen).
For stable transduction, PTM-R50 was subcloned into the retroviral
vector pLXSN (PTM-R50) after introducing EcoRI and BamHI
restriction sites by PCR amplification (forward: GATGAATTCGA
GGCCATGTCGGG, reverse: GATGGATCCCAACCACGCCGGGCTCT).
Retroviral constructs were generated by digesting vector and
insert with the appropriate restriction enzymes, gel purification,
and ligation with T4 DNA ligase (New England Biolabs, Beverly,
MA) overnight at 161C, followed by transformation into the
chemically competent Escherichia coli strain DH5aTM-T1 (Invitrogen,
Karlsruhe, Germany) and grown on lactose broth-ampicillin plates
for selection. Cloning into the expression vectors was performed as
suggested by the manufacturer’s protocol (Invitrogen). Positive
clones were identified by colony-PCR. The correct insert was
confirmed by restriction digests and verified by DNA sequencing
analysis.
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Transient transfections
Human fibroblasts were grown in fibroblast basal medium (Promo-
Cell, Heidelberg, Germany)/10% newborn calf serum (NCS) to
B80–90% confluency. The media was changed using antibiotic- and
serum-free media; then the cells were transfected with 2–4 mg of
plasmid (PTM-E50, pmaxGFP) using AMAXA Human Dermal
Fibroblast Nucleofector kit (AMAXA GmbH, Germany). After
incubation at 371C for 48 hours and 7 days, respectively, cells were
harvested for RNA and protein analysis.
Production of PT67 retroviral producer line using RetroX
System (Clontech, Palo Alto, CA)
RetroPack PT67 cells were used for virus production. PTM-R50 or pLXSN
(vector control) were separately transfected into the mouse NIH-3T3
fibroblast-derived cell line PT67 as described above. Virus production
was performed according to the manufacturer’s protocol. Several dilutions
were plated to facilitate isolation of single colonies. After 3 days of
growth, G418-containing medium was added to select for transfected
cells. At the stage of 20–50 cells per colony, single colonies were picked
and grown separately. After 14 days, cells were frozen and supernatants
were analyzed by PCR (using vector-specific primers pLXSNfw and
pLXSNrv; Clontech) and by sequence analysis for the presence of virus
particles containing either the entire PTM-R50 or the empty vector.
Determination of viral titers
The infective potential of positive viral supernatants was tested by
infecting NIH-3T3 mouse fibroblasts with six serial dilutions of the
supernatants VS1, VS6, and VS24. After 3 days of growth, G418 was
added to the medium to select for infected cells. An uninfected
control plate was grown in parallel as a control. Cells were grown for
another 14 days with a change of medium every other day. Viral
titers were determined by counting the remaining colonies in the
well with the highest dilution and multiplying by the dilution factor.
Infection of patient cells
Primary fibroblasts from an EBS-MD patient were grown to a
confluency of 70%. Infection was performed as described by the
manufacturer’s protocol using the supernatant with the highest viral
titer (VS1). After 48 hours, RNA and protein were isolated for analysis
by real-time PCR and immunoblotting.
RNA preparation and RT-PCR
Total RNA was isolated using Epicenter MasterPureTM RNA Purifica-
tion Kit (Epicenter Biotechnologies, Madison, WI). Contaminated
plasmid and genomic DNA were eliminated by treating with DNase
I (Sigma, St Louis, MA). cDNA was synthesized from 100ng total
RNA using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA).
cDNA containing the region of interest (1287ins3) was amplified
using primers that flank the mutation, PLEC1 exon 9 forward
(gatgaattcgagctgcagctgcg) and PLEC1 exon 10 reverse (ctccagg-
gattggtagatgcccttgg). Sequence analysis verified that the correct
product was generated.
Normalization was performed with the housekeeping gene
GAPDH as an internal control.
DNA Sequencing
DNA sequencing of 20 ng DNA/100 bp with 10pmol of the
respective primers was performed by MWG-Biotech.
SQRT-PCR
Primer combinations were tested by PCR of wild-type and
patient cDNA to determine the best conditions for high specificity.
SQRT-PCR was performed with Bio-Rad iCyclerTM and Bio-Rad iQTM
SYBR Green Supermix Kit (Bio-Rad). Each primer of 15 pmol was
added to the reactions. To minimize pipetting errors, reactions were
prepared as master mixes. As a reference for semiquantitative
analysis, we used the housekeeping gene GAPDH, after rejecting
actin-b, RPLP0, and tubulin (GAPDH: forward, gccaacgtgtcagtggtg-
ga; reverse, caccaccctgttgctgtagcc). For discriminiation between
wild-type and mutated alleles a wild-type-specific forward primer
for plectin exon 9 was designed. (PLEC1 exon 9 wt forward:
gagctggtgctgctgctgcttcag PLEC1 exon 10 reverse: ctccagggattggta
gatgcccttgg.)
cDNA (50 ng) from either PTM-transfected, mock-transfected
EBS-MD, or wild-type fibroblasts were used for each reaction.
Cycling conditions were 5minutes at 951C, 30 s at 951C, 20 s at
651C, 20 s at 721C, followed by melt curve analysis (8 seconds each
degree). Data were collected during each cycle and analyzed by the
manufacturer’s software. After the amplification, 5ml of each real-
time PCR product was analyzed on an agarose gel.
Cross-gene PCR analysis for plectin and related plakin genes
Genes of the plakin gene family encode desmoplakin, envoplakin,
epiplakin, dystonin, periplakin, and microtubule-actin crosslinking
factor 1. Possible illegitimate PTM-binding sites in each of those
genes were identified using the MultAlin sequence alignment tool.
Intronic sequences of the plakin genes were aligned with the
sequence of the PTM-binding site located in intron 9 of PLEC1.
Several possible PTM-binding sites in each plakin gene, as well as
another binding site further downstream in the plectin gene were
obtained. Specific reverse exonic primers downstream of the
putative PTM-binding sites in the plakin genes were designed and
PCR analysis in combination with a forward primer specific to
plectin exon 9 was performed. A reverse primer for plectin exon 10
was added to the reaction mix to act as a positive control. PCR
analysis was performed on cDNA from PTM-transfected and non-
transfected EBS-MD fibroblasts.
Isolation of total protein from cultured cells
Cells were washed three times with phosphate-buffered saline
and scraped off with a cell scraper. After centrifugation, cells
were resuspended in 200ml cell lysis buffer (0.5M Tris–HCl, pH
6.8, 20% glycine, 10% SDS, 5% b-mercaptoethanol, and
1 complete protease inhibitor cocktail; Roche, Mannheim,
Germany). The lysate was passed through a 22G syringe several
times to disrupt cell aggregations and incubated at 951C for
10minutes.
Immunofluorescence
Cells were grown to about 75% confluency and fixed with 4%
formaldehyde in phosphate-buffered saline. Cells were blocked for
1 hour with 10% normal swine serum, 0.1% BSA, 0.5% Triton
X-100, and then incubated with 1:4 diluted mouse-derived mAb 5B3
to plectin (12). Biotin-labeled anti-mouse IgG antibody was used as a
secondary antibody (Bio-Rad, Hercules) and visualized with
cyanine-3-streptavidin conjugate from Amersham Pharmacia
(Uppsala, Sweden).
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Western blot analysis
SDS-PAGE. Total protein concentrations were determined by
Bradford Assay (Bio-Rad) and equal amounts were applied on a
10% NuPAGE Bis-Tris-Gel (Invitrogen). Gels were run for 1 hour at
160V. Proteins were blotted onto Hybond ECL 7 8 cm membranes
(Amersham Pharmacia) for 1 hour at 0.8A. After blocking for 1 hour
with blocking buffer (200mmol Tris–HCl, pH 7.6, 137mmol NaCl,
0.2% I-Block (w/v), 0.1% Tween-20 (v/v)), mouse-derived mAb 5B3
diluted 1:4 in blocking buffer was added, and the membrane was
incubated overnight at 41C. Subsequent washing with blocking
buffer was followed by incubation with 1:3,000 diluted alkaline
phosphatase-linked anti-mouse-IgG (Sigma) for 1.5 hours. Specific
bands were visualized with CDP-Star reagent from New England
Biolabs.
The study was conducted according to the institutional regulation
of experiments and adherence to the Declaration of Helsinki
Principles.
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